After neurodegeneration miss, Retrophin looks to rebound with renal program

With plans to discontinue fosmetpantotenate after its Phase III miss, Retrophin President and CEO Eric Dube believes the $425 million with which it ended last quarter is enough to bring its remaining clinical candidate to market.

Dube’s comments came Thursday on a conference call following fosmetpantotenate's failure to meet the primary and secondary endpoints in the Phase III FORT trial to treat pantothenate kinase-associated neurodegeneration (PKAN). The results drove shares of Retrophin Inc. (NASDAQ:RTRX) down $3.84 (22%) to $13.56 Thursday, well below its 52-week high of $33...